Article Details
Retrieved on: 2021-03-16 16:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
LUCENT-1 is the first and only Phase 3 study of an anti-IL-23p19 monoclonal antibody to demonstrate reduced bowel urgency in moderate to severe ...
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here